The Effect of Sujok Therapy on Cancer Symptoms
1 other identifier
interventional
49
1 country
1
Brief Summary
The aim of this study is to determine the effect of Sujok therapy on Pain, Fatigue, Insomnia, Nausea and Vomiting experienced by patients with gastrointestinal system cancer.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable cancer
Started Feb 2022
Shorter than P25 for not_applicable cancer
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2022
CompletedFirst Submitted
Initial submission to the registry
February 4, 2022
CompletedFirst Posted
Study publicly available on registry
March 4, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
September 5, 2022
CompletedFebruary 24, 2023
February 1, 2023
4 months
February 4, 2022
February 22, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (4)
Sujok Therapy's Positive Change in Pain Experienced by Gastrointestinal System Cancer Patients
To assess the pain, the MCgill Pain Scale will be applied before starting the sujok application and after the sujok applied for 2 weeks.
2 weeks
Sujok Therapy's positive change in Fatigue Experienced by Patients with Gastrointestinal System Cancer
To assess the fatigue, the cancer fatigue scale will be applied before starting the sujok application and after the sujok applied for 2 weeks.
2 weeks
Sujok Therapy's positive cahange in insomnia Experienced by Patients with Gastrointestinal System Cancer
In order to evaluate insomnia,the insomnia severity index will be applied before starting the sujok application and after the sujok applied for 2 weeks
2 weeks
Sujok Therapy's positive cahange in nausea and vomiting Experienced by Patients with Gastrointestinal System Cancer
To evaluate nausea and vomiting, the Rhodes nausea vomiting scale will be applied before starting the sujok application and after the sujok applied for 2 weeks
2 weeks
Study Arms (2)
Experimental group
EXPERIMENTALIn the hand area, firstly, the points will be determined by means of the diagnostic stick and massage will be applied with buckwheat seeds. This massage will be 3 sessions a week, and a total of 6 sessions in 2 weeks.
control group
NO INTERVENTIONA questionnaire will be applied to the patients by the researcher. Questionnaires will be made as pre-test and post-test.
Interventions
Eligibility Criteria
You may qualify if:
- over 18 years old
- Fatigue Severity Measurement - Visual Analogue Scale (VAS) fatigue score of 3 and above,
- Pain Severity Measurement - Visual Analogue Scale (VAS) pain score of 3 and above,
- Measurement of Nausea and Vomiting Severity - Patients with a Visual Analogue Scale (VAS) nausea and vomiting score of 3 and above will be included.
You may not qualify if:
- Loss of sensation, amputation, injury, colostomy, etc., which will prevent practice in hands. patients will be excluded from the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Atatürk Universty
Erzurum, Turkey (Türkiye)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
February 4, 2022
First Posted
March 4, 2022
Study Start
February 1, 2022
Primary Completion
June 1, 2022
Study Completion
September 5, 2022
Last Updated
February 24, 2023
Record last verified: 2023-02
Data Sharing
- IPD Sharing
- Will not share